Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
Abstract This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma...
Saved in:
Main Authors: | Run-Cong Nie, Shu-Qiang Yuan, Ya Ding, Yong-Ming Chen, Yuan-Fang Li, Cheng-Cai Liang, Mu-Yan Cai, Guo-Ming Chen, Wei Wang, Xiao-Wei Sun, De-Sheng Weng, Dan-Dan Li, Jing-Jing Zhao, Xiao-Jiang Chen, Yuan-Xiang Guan, Zhi-Min Liu, Yao Liang, Ma Luo, Jun Chi, Hai-Bo Qiu, Zhi-Wei Zhou, Xiao-Shi Zhang, Ying-Bo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-02-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-025-02160-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive three-dimensional microCT and signaling analysis reveal the teratogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on craniofacial bone development in mice
by: Xiao-ming Wang, et al.
Published: (2025-01-01) -
Identification of deep intronic variants in junctional epidermolysis bullosa using genome sequencing and splicing assays
by: Fuying Chen, et al.
Published: (2025-02-01) -
Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study
by: Shan Chen, et al.
Published: (2013-12-01) -
Unmasking MRSA antibiotic resistance: the impact of environment, pollution, and healthcare quality—a nationwide exploration in China: a comprehensive analysis spanning 2014 to 2021 in mainland China
by: Yi-Chang Zhao, et al.
Published: (2025-02-01) -
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01)